Skip to main content
Caplight Logo









Evonetix

Evonetix

Private
CambridgeHealthcare & Life Scienceshttp://evonetix.com/cgi-sys/suspendedpage.cgi

Last Round

Series B

Extension

Feb 7, 2023

Est. Valuation

$108.16M

Total Funding Raised

$68.05M

Company Overview

Evonetix is a biotechnology company that develops DNA synthesis technology utilizing a specialized electronic silicon chip approach to produce high-fidelity genetic material.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Biotech Equipment, Drug Discovery, Semiconductors

Business Model

B2B

Customer Profile

Hardware Sales, Hardware + Subscription

AI Layer

Non-AI

Keywords

DNA synthesissynthetic biologyDNA synthesis platformbenchtop DNA synthesissemiconductor-based synthesissynthetic DNADNA printingbiotech hardwaregenomicsdrug discoverymolecular diagnosticsrazor-and-blades modellab automation

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Evonetix Comparables

Compare Evonetix with similar companies based on industry and business-model similarity.

Evonetix comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
DNA Script
83%
Switchback Systems
83%
Telesis Bio
80%

Evonetix Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series B ExtensionFeb 7, 2023
Series BMar 2, 2020
GrantJul 2, 2018
Series AJan 30, 2018

Key People

Founding team and executive leadership

Andrew Diston

Chief Executive Officer

Executive Team

Evonetix Investors

Notable investors and investment history

Evonetix investors
InvestorRounds
Rising Tide FundSeries A, Series B
Innovate UKGrant
Providence Equity PartnersSeries B
UK governmentGrant
Morningside VenturesSeries A, Series B
Innovate UKGrant
Foresite CapitalSeries B Extension, Series B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 2, 2020

    $30M round led by Foresite Capital

  • Jul 2, 2018

    Secured $1.75M from Innovate UK and the UK government.

Evonetix Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Evonetix Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Evonetix's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge
Employee Range11
Year Founded2015
Last FundingFeb 7, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?